Edition:
United States

Ultragenyx Pharmaceutical Inc (RARE.OQ)

RARE.OQ on NASDAQ Stock Exchange Global Select Market

45.24USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$45.24
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
159,508
52-wk High
$91.17
52-wk Low
$44.05

Latest Key Developments (Source: Significant Developments)

ULTRAGENYX SAYS FDA APPROVES MEPSEVII FOR GENETIC DISEASE MUCOPOLYSACCHARIDOSIS VII
Wednesday, 15 Nov 2017 01:22pm EST 

Nov 15 (Reuters) - Ultragenyx Pharmaceutical Inc ::ULTRAGENYX ANNOUNCES FDA APPROVAL OF MEPSEVII™ (VESTRONIDASE ALFA), THE FIRST THERAPY FOR PROGRESSIVE AND DEBILITATING RARE GENETIC DISEASE MUCOPOLYSACCHARIDOSIS VII.ULTRAGENYX PHARMACEUTICAL - OPINION FOR VESTRONIDASE ALFA FROM COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE IS EXPECTED IN H1 2018​.ULTRAGENYX PHARMACEUTICAL INC - ‍MEPSEVII WILL BE AVAILABLE TO PATIENTS IN U.S. LATER IN NOVEMBER​.  Full Article

FDA approves Ultragenyx Pharmaceutical's Mepsevii for rare genetic enzyme disorder‍​
Wednesday, 15 Nov 2017 11:55am EST 

Nov 15 (Reuters) - FDA::Approved Ultragenyx Pharma's Mepsevii to treat pediatric, adult patients with inherited metabolic condition called mucopolysaccharidosis TYPE VII ‍​.  Full Article

Ultragenyx reports third quarter 2017 financial results
Thursday, 2 Nov 2017 04:05pm EDT 

Nov 2 (Reuters) - Ultragenyx Pharmaceutical Inc :Ultragenyx Pharmaceutical Inc- ‍cash, cash equivalents, and investments were $396.0 million as of September 30, 2017​.Q3 loss per share $1.87.Q3 earnings per share view $-1.86 -- Thomson Reuters I/B/E/S.  Full Article

ULTRAGENYX AND KYOWA HAKKO KIRIN ANNOUNCE FDA ACCEPTANCE OF BUROSUMAB’S BIOLOGICS LICENSE APPLICATION
Tuesday, 10 Oct 2017 08:30am EDT 

Oct 10 (Reuters) - Ultragenyx Pharmaceutical Inc ::ULTRAGENYX AND KYOWA HAKKO KIRIN ANNOUNCE FDA ACCEPTANCE AND PRIORITY REVIEW DESIGNATION OF BUROSUMAB’S BIOLOGICS LICENSE APPLICATION.ULTRAGENYX PHARMACEUTICAL INC - ‍PRESCRIPTION DRUG USER FEE ACT (PDUFA) ACTION DATE FOR BLA IS APRIL 17, 2018​.ULTRAGENYX PHARMACEUTICAL INC - FDA HAS NOT INFORMED COMPANIES WHETHER AN ADVISORY COMMITTEE MEETING TO DISCUSS APPLICATION WILL BE NEEDED​.ULTRAGENYX - FDA ACCEPTED BLA FOR BUROSUMAB TO TREAT PEDIATRIC, ADULT PATIENTS WITH X-LINKED HYPOPHOSPHATEMIA, GRANTED PRIORITY REVIEW STATUS​.  Full Article

Dimension Therapeutics says on termination of merger with Ultragenyx co will be required to pay Ultragenyx a termination fee of $2.9 mln-SEC filing
Tuesday, 3 Oct 2017 08:59am EDT 

Oct 3 (Reuters) - Dimension Therapeutics Inc ::Dimension Therapeutics says on termination of merger with Ultragenyx co will be required to pay Ultragenyx a termination fee of $2.9 million-SEC filing.Dimension Therapeutics-co to reimburse Ultragenyx for $2.9 million fee paid by Ultragenyx on behalf of dimension for termination of Regenxbio deal.  Full Article

Ultragenyx to acquire Dimension Therapeutics
Tuesday, 3 Oct 2017 08:30am EDT 

Oct 3 (Reuters) - Ultragenyx Pharmaceutical Inc : :Ultragenyx to acquire Dimension Therapeutics.Ultragenyx Pharmaceutical Inc - deal for ‍$6.00 per share​.Ultragenyx Pharmaceutical Inc - deal for ‍approximately $151 million in cash​.Ultragenyx Pharmaceutical Inc - ‍transaction is structured as a tender offer and will be funded through ultragenyx's existing cash resources​.Ultragenyx Pharmaceutical Inc - ‍ultragenyx will pay regenxbio a termination fee pursuant to regenxbio merger agreement, on behalf of dimension​.Ultragenyx Pharmaceutical Inc - tender offer is not subject to a financing condition.  Full Article

Ultragenyx Pharmaceutical comments on Dimension Therapeutics' announcement
Monday, 2 Oct 2017 09:22am EDT 

Oct 2 (Reuters) - Ultragenyx Pharmaceutical: :Ultragenyx Pharmaceutical comments on dimension therapeutics' announcement that co's offer is a "superior proposal" in its merger agreement with regenxbio.Ultragenyx Pharmaceutical says is "pleased" that dimension board determined that all-cash offer to buy dimension for $6.00 per share is a superior proposal.  Full Article

Dimension board determines Ultragenyx’s unsolicited proposal constitutes a “superior proposal”
Monday, 2 Oct 2017 08:00am EDT 

Oct 2 (Reuters) - Dimension Therapeutics Inc :Dimension board determines that Ultragenyx’s unsolicited proposal to acquire dimension for $6.00 per share constitutes a “superior proposal”.Dimension Therapeutics Inc - ‍dimension board has not changed its recommendation in support of REGENXBIO transaction​.  Full Article

DIMENSION CONFIRMS RECEIPT OF UNSOLICITED PROPOSAL FROM ULTRAGENYX
Monday, 18 Sep 2017 03:10pm EDT 

Sept 18 (Reuters) - Dimension Therapeutics Inc :DIMENSION CONFIRMS RECEIPT OF UNSOLICITED PROPOSAL FROM ULTRAGENYX.‍BOARD WILL CAREFULLY REVIEW AND CONSIDER ULTRAGENYX PROPOSAL​.‍DIMENSION'S BOARD OF DIRECTORS HAS NOT CHANGED ITS RECOMMENDATION IN SUPPORT OF MERGER WITH REGENXBIO​.‍MTS HEALTH PARTNERS L.P. IS SERVING AS FINANCIAL ADVISOR TO DIMENSION​.  Full Article

Ultragenyx proposes to acquire Dimension Therapeutics for $5.50 per share in cash
Monday, 18 Sep 2017 08:35am EDT 

Sept 18 (Reuters) - Ultragenyx Pharmaceutical Inc :Ultragenyx proposes to acquire Dimension Therapeutics for $5.50 per share in cash.Ultragenyx Pharmaceutical Inc - ‍proposal has been approved by board of directors of Ultragenyx​.Ultragenyx Pharmaceutical Inc - ‍has made a proposal to acquire all of outstanding shares of common stock of Dimension Therapeutics for about $138 million​.Ultragenyx Pharmaceutical Inc - ‍Ultragenyx would fund proposed transaction from cash resources on its balance sheet​.Ultragenyx Pharmaceutical - ‍proposed all-cash transaction structured as a tender offer.  Full Article

BRIEF-Ultragenyx And Kyowa Kirin Announce Positive 48-Week Data From Adult Phase 3 Study Of Burosumab In X-Linked Hypophosphatemia

* ULTRAGENYX AND KYOWA KIRIN ANNOUNCE POSITIVE 48-WEEK DATA FROM ADULT PHASE 3 STUDY OF BUROSUMAB (KRN23) IN X-LINKED HYPOPHOSPHATEMIA Source text for Eikon: Further company coverage: